Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  EntreMed Inc    

SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Develops pharmaceutical drugs for treating cancer and inflammatory diseases

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs with commercial focus on the China market.

The Company operates through one business segment, which is the development of targeted therapeutics primarily for the treatment of cancer.

The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau.

The drugs are Captisol-Enabled, ZEVALIN and MARQIBO.

CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.
Managers
NameAgeSinceTitle
Ken Keyong Ren MD, PhD572012Chief Executive Officer & Director
Wei-Wu He PhD, MBA512012Executive Chairman
Cynthia Wong Hu462006COO, Secretary, Vice President & General Counsel
Sara B. Capitelli, CPA492011Chief Accounting Officer & Vice President-Finance
Rong Chen MD, PhD-2015Chief Medical Officer
Zuie Chin Huang, MBA502013Independent Director
Yue Alexander Wu PhD, MBA522013Independent Director
Franklin Cary Salisbury, Jr.602014Independent Director
Rajesh C. Shrotriya, MD722014Independent Director
Quan Zhou, PhD582016Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 42,662,846 19,709,521 46.2% 79,545 0.2% 46.2%
Shareholders
NameEquities%
Spectrum Pharmaceuticals, Inc. 7,094,259 16.7%
IDG Capital Partners Co., Ltd. 6,842,783 16.1%
He Xie Ai Qi Investment Management Beijing Co. Ltd. 4,744,910 11.1%
Zhejiang Kanglaite Group Co. Ltd. 2,057,613 4.83%
Wellington Shields Capital Management LLC 561,408 1.32%
Wellington Shields & Co. LLC 489,327 1.15%
Emerging Technology Partners LLC 441,072 1.04%
Kleiner Perkins Caufield & Byers LLC 416,666 0.98%
The Vanguard Group, Inc. 382,798 0.90%
Tak W. Mak, PhD 365,376 0.86%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
INCYTE CORPORATIO..
CELLTRION, INC.
LONZA GROUP AG
QUINTILES TRANSNA..
ALKERMES PLC
SEATTLE GENETICS,..
QIAGEN NV
ANACOR PHARMACEUT..
ALNYLAM PHARMACEU..
UNITED THERAPEUTI..
BIO-TECHNE CORP
ICON PLC
CHARLES RIVER LAB..
ACADIA PHARMACEUT..
PAREXEL INTERNATI..
INTREXON CORP
BB BIOTECH AG
-
IONIS PHARMACEUTI..
PRA HEALTH SCIENC..
LIGAND PHARMACEUT..
Sector Biotechnology & Medical Research
EntreMed Inc : Connections
IDG Technology Venture Investment, Inc.
Emerging Technology Partners LLC
Superdata Technology (Asia) Ltd.
Amnis Corp.
MithraGen, Inc.
Wuhan Kindstar Diagnostics Co., Ltd.
Intradigm Corp.
Crown Bioscience, Inc.
IDG Technology Venture Investment IV LLC
Cytomyx Holdings Plc
OriGene Technologies, Inc.
National Foundation for Cancer Research
WUPIMA, Inc.
Allos Therapeutics, Inc.
Creditease Holdings Cayman Ltd.
ImmunoVentis, Inc.
CVie Therapeutics Co. Ltd.
Zenesis Ltd.
IDG Capital Partners Co., Ltd.
Chiral Quest (Suzhou) Co. Ltd.
Circle Internet Financial, Inc.
OMNI Pharmaceuticals (USA), Inc.
American-Sino OB/GYN Hospital
Smooth Prosper Ltd.
IDG Technology Venture Investment III LLC
KPCB China Fund II LP
IDG Technology Venture Investments LP
Company contact information
CASI Pharmaceuticals, Inc.
9620 Medical Center Drive
Suite 300
Rockville, MD 20850

Phone : +1.240.864.2600
Fax : +1.240.315.2437
Web : www.casipharmaceuticals.com
© 2016 People , Fundamentals and Ownership